Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/69aa276b-d53f-4877-82f6-2d5c0a5602d6/

DMP

Dermapharm Holding SE
Chart
45.50 EUR
Latest Week 2026-07-10
HealthcareDrug Manufacturers - Specialty & GenericMID
Snapshot 2026-07-12 · 0.7w · Fresh
0.93
OS Score
65.0%
Value
94.0%
Quality
78.0%
Momentum
8/9
F-Score
0.782
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
8 of 23 passing
★
OS Composite
OS 0.930
↗
Trending Value
✗
◆
Quality × Value
QV 0.782
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
10.9%
◐
Veiled Value
✗
▣
Piotroski Bargains
F8
🔬
Quality Compounders
✗
📈
Consistent Earners
Yes
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 39%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 1.00
⚡
Risk-Adj Momentum
RAM 1.40
V
Value Analysis
Cheapness relative to fundamentals
65.0%ile
P/E
15.6×
P/S
1.9×
P/B
3.1×
E/P
0.0772
FCF Yield
0.078
EBITDA/EV
0.109
SH Yield
0.019
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
42.00000000
/100 — 1=cheapest
VC2 (Trending Value)
60.00000000
/100
VC3 (Buyback)
62.00000000
/100
FCF yield of 7.8% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
94.0%ile
ROE
0.195
ROA
0.063
Net Margin
0.123
Op Margin
0.204
GPA
0.348
Current
2.00
F-Score
8/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
-0.013
Earn Growth
0.164
Stability
0.262
lower=better
Accruals
-0.062
lower=better
5yr Consist
Yes
F-Score of 8/9 indicates strong fundamental improvement across multiple dimensions.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
78.0%ile
6M Return
19.0%
12M Return
32.8%
12-1 Mom
39.4%
Risk-Adj
1.40
Vol 252d
28.1%
Vol 60d
68.3%
↑ Expanding
Max DD 12M
-10.5%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 39% is very strong — a clear uptrend. Near-term vol (68%) is expanding vs long-term (28%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.93
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 77 peers
Sector Value %ile
76.9%
Sector Quality %ile
91.0%
P/E z-score
-0.35
P/B z-score
-0.19
Sector Avg OS
48.7%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
MED MEDICLIN Aktiengesellschaft 98.0% 97.0% 82.0% 79.0%
DRW8 Drägerwerk AG & Co. KGaA 96.0% 96.0% 58.0% 72.0%
NOV Novo Nordisk A/S 96.0% 98.0% 83.0% 38.0%
CBHD Coloplast A/S 96.0% 98.0% 92.0% 29.0%
DRW3 Drägerwerk AG & Co. KGaA 95.0% 91.0% 59.0% 73.0%
M12 M1 Kliniken AG 94.0% 74.0% 92.0% 70.0%
BRM Bristol-Myers Squibb Company 93.0% 66.0% 98.0% 74.0%
NN6 NanoRepro AG 91.0% 75.0% 70.0% 76.0%
Factor Interactions
Piotroski + Value Convergence
F-Score 8/9 with good value (65th). Strong fundamental improvement in a cheap stock.
Volatility Expanding
60-day vol (68%) significantly exceeds 252-day (28%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
62.9% avg (7 factors)
Quality
B
61.7% avg (7 factors)
Momentum
B
69.2% avg (4 factors)
Risk
B
69.9% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends6 snapshots
Factor Persistence6 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.930—6—
Value %ile0.650—0—
Quality %ile0.940—6—
Momentum %ile0.780—6—
F-Score8.000—6—
Confidence0.920—6—
Volatility0.281—0—
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
15.63
Earnings Yield (E/P)
0.0772
Price / Sales
1.93
Price / Book
3.05
Price / Cash Flow
7.92
FCF Yield
7.8%
EBITDA / EV
10.9%
Sales Yield (1/P·S)
0.3788
Shareholder Yield
Div + net buyback / mktcap
1.9%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
19.5%
Return on Assets
6.3%
Net Margin
12.3%
Operating Margin
20.4%
Gross Profit / Assets
Novy-Marx GPA
34.8%
Current Ratio
2.00
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.062
MomentumPrice trend strength over different horizons
6M Return
19.0%
12M Return
32.8%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
39.4%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
1.40
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
-1.3%
Earnings Growth (YoY)
16.4%
Earnings Stability (CV)
Lower = more stable
0.262
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
8
Dividend Yield
1.9%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
42
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
60
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
62
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity